Additional file 1: Table S1. of Utilization patterns of insulin therapy and healthcare services among Japanese insulin initiators during their first year: a descriptive analysis of administrative hospital data

Classification of insulin. (DOCX 79 kb

Supplementary Tables: Economic burden in treated Japanese patients with relapsed/refractory large B-cell lymphoma.xlsx

Supplementary Table 1. Exchange rate and inflation rate conversion table. Supplementary Table 2. Additional baseline and treatment characteristics Supplementary Table 3. Distribution of patients by age group in each index regimen Supplementary Table 4. Median index dosage for each regimen Supplementary Table 5. Healthcare resource utilization during the follow-up period, by line of therapy and by index regimen. Supplementary Table 6. Age at SCT by age groups and line of therapy Supplementary Table 7. Adjusted direct nominal medical costs during the follow-up period, by line of therapy and by index regimen. Supplementary Table 8. Additional HCRU results for COVID-19 analysis. </div

Treatment patterns for rrDLBLC patients.

Treatment patterns for rrDLBLC patients.</p

Supp_Figure_1a: Economic burden in treated Japanese patients with relapsed/refractory large B-cell lymphoma.tif

Supplemental Figure 1a - Patient attrition for 2L and 3L r/r DLBCL patients - Main analysis cohort </div

Supp_Figure_1b: Economic burden in treated Japanese patients with relapsed/refractory large B-cell lymphoma.tif

Supplemental Figure 1b - Patient attrition for 2L and 3L r/r DLBCL patients - COVID-19 analysis cohort. </div

Suppl_Figure_2: Economic burden in treated Japanese patients with relapsed/refractory large B-cell lymphoma.tiff

Supplemental Figure 2 - Claims between 1st March and 30th June 2019 for the pre-COVID-19 subgroup were analyzed in comparison with claims between 1st March and 30th June 2020 for the post-COVID-19 subgroup </div

Supplementary Figure 2. Real world assessment of myelodysplastic syndrome: Japanese claims data analysis

Supplementary Figure 2. Total and cost categories by 12-month period for each regimen group. (A) [Transfusion], (B) [ESA], (C) [ESA + transfusion], (D) [AZA], (E) [AZA + transfusion], (F) [Other] regimens. AZA, azacitidine; ESA, erythropoiesis-stimulating agents; ICU, intensive care unit

Standardized estimates from structural equation model of 2L and 3L cost drivers.

Standardized estimates from structural equation model of 2L and 3L cost drivers.</p

Supplementary Tables. Real world assessment of myelodysplastic syndrome: Japanese claims data analysis

Supplementary Table 1. Inflation adjustment based on calendar year averages.Supplementary Table 2. Nominal cost outcomes up to 3-year follow-up (LS-means and p-value were adjusted for all baseline comorbidities)Supplementary Table 3. Nominal cost outcomes up to 3-year follow-up among HSCT groupsSupplementary Table 4. Additional patient baseline characteristics overall and by treatment categorySupplementary Table 5. Baseline characteristics for ESA and AZA patients who had transfusion within the first year of follow-upSupplementary Table 6. Median cost (USD) for each treatment group over 3-years and stratified by follow-up monthSupplementary Table 7. Baseline characteristics for patients with incremental TDSupplementary Table 8. Health care resource utilization stratified by follow-up month</div

SEM pathway diagram used for each cohort.

Solid lines indicate relationship specified as direct effect on THCC in the model and dotted lines indicate relationship specified as indirect effect on THCC via mediator(s) in the model.</p